These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 33915409)
1. Extracellular matrix-inspired inhalable aerogels for rapid clearance of pulmonary tuberculosis. Simonson AW; Umstead TM; Lawanprasert A; Klein B; Almarzooqi S; Halstead ES; Medina SH Biomaterials; 2021 Jun; 273():120848. PubMed ID: 33915409 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
4. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis. Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748 [TBL] [Abstract][Full Text] [Related]
5. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
6. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Man DK; Chow MY; Casettari L; Gonzalez-Juarrero M; Lam JK Adv Drug Deliv Rev; 2016 Jul; 102():21-32. PubMed ID: 27108702 [TBL] [Abstract][Full Text] [Related]
8. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
9. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
10. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum. Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524 [TBL] [Abstract][Full Text] [Related]
11. Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Eoh H; Liu R; Lim J; Lee JJ; Sell P Front Cell Infect Microbiol; 2022; 12():958240. PubMed ID: 36072228 [TBL] [Abstract][Full Text] [Related]
12. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
13. Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment. Silva JP; Gonçalves C; Costa C; Sousa J; Silva-Gomes R; Castro AG; Pedrosa J; Appelberg R; Gama FM J Control Release; 2016 Aug; 235():112-124. PubMed ID: 27261333 [TBL] [Abstract][Full Text] [Related]
14. Drug-Tolerant Ufimtseva EG; Eremeeva NI Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834390 [TBL] [Abstract][Full Text] [Related]
15. Shim D; Kim H; Shin SJ Front Immunol; 2020; 11():910. PubMed ID: 32477367 [TBL] [Abstract][Full Text] [Related]
16. Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages. Lee HJ; Ko HJ; Kim SH; Jung YJ PLoS One; 2019; 14(3):e0199799. PubMed ID: 30865638 [TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicles Released from Alvarez-Jiménez VD; Leyva-Paredes K; García-Martínez M; Vázquez-Flores L; García-Paredes VG; Campillo-Navarro M; Romo-Cruz I; Rosales-García VH; Castañeda-Casimiro J; González-Pozos S; Hernández JM; Wong-Baeza C; García-Pérez BE; Ortiz-Navarrete V; Estrada-Parra S; Serafín-López J; Wong-Baeza I; Chacón-Salinas R; Estrada-García I Front Immunol; 2018; 9():272. PubMed ID: 29520273 [TBL] [Abstract][Full Text] [Related]
18. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents. Elsaman T; Mohamed MS; Mohamed MA Bioorg Chem; 2019 Jul; 88():102969. PubMed ID: 31077910 [TBL] [Abstract][Full Text] [Related]
19. [Prospects for development of new antituberculous drugs]. Tomioka H Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850 [TBL] [Abstract][Full Text] [Related]
20. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis? Park HE; Lee W; Shin MK; Shin SJ Front Immunol; 2021; 12():703060. PubMed ID: 34262571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]